PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond

Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are approved for <i>BRCA1/2</i> carriers with HER2-negative breast cancer in the adjuvant setting with a high risk of recurrence as well as the metastatic setting. However, the indications for PARPi are broader for patients with other cancer types (e.g., prostate and ovarian cancer), involving additional biomarkers (e.g., <i>ATM</i>, <i>PALB2</i>, and <i>CHEK</i>) and genomic instability scores. Herein, we summarize the data on PARPi and breast cancer and discuss their use beyond <i>BRCA</i> carriers.